324 related articles for article (PubMed ID: 20827286)
1. Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM).
Lacy MQ; Hayman SR; Gertz MA; Short KD; Dispenzieri A; Kumar S; Greipp PR; Lust JA; Russell SJ; Dingli D; Zeldenrust S; Fonseca R; Bergsagel PL; Roy V; Mikhael JR; Stewart AK; Laumann K; Allred JB; Mandrekar SJ; Rajkumar SV; Buadi F
Leukemia; 2010 Nov; 24(11):1934-9. PubMed ID: 20827286
[TBL] [Abstract][Full Text] [Related]
2. Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma.
Lacy MQ; Hayman SR; Gertz MA; Dispenzieri A; Buadi F; Kumar S; Greipp PR; Lust JA; Russell SJ; Dingli D; Kyle RA; Fonseca R; Bergsagel PL; Roy V; Mikhael JR; Stewart AK; Laumann K; Allred JB; Mandrekar SJ; Rajkumar SV
J Clin Oncol; 2009 Oct; 27(30):5008-14. PubMed ID: 19720894
[TBL] [Abstract][Full Text] [Related]
3. Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study.
Kelly KR; Ailawadhi S; Siegel DS; Heffner LT; Somlo G; Jagannath S; Zimmerman TM; Munshi NC; Madan S; Chanan-Khan A; Lonial S; Chandwani S; Minasyan A; Ruehle M; Barmaki-Rad F; Abdolzade-Bavil A; Rharbaoui F; Herrmann-Keiner E; Haeder T; Wartenberg-Demand A; Anderson KC
Lancet Haematol; 2021 Nov; 8(11):e794-e807. PubMed ID: 34529955
[TBL] [Abstract][Full Text] [Related]
4. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.
Richardson PG; Oriol A; Beksac M; Liberati AM; Galli M; Schjesvold F; Lindsay J; Weisel K; White D; Facon T; San Miguel J; Sunami K; O'Gorman P; Sonneveld P; Robak P; Semochkin S; Schey S; Yu X; Doerr T; Bensmaine A; Biyukov T; Peluso T; Zaki M; Anderson K; Dimopoulos M;
Lancet Oncol; 2019 Jun; 20(6):781-794. PubMed ID: 31097405
[TBL] [Abstract][Full Text] [Related]
5. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
Miguel JS; Weisel K; Moreau P; Lacy M; Song K; Delforge M; Karlin L; Goldschmidt H; Banos A; Oriol A; Alegre A; Chen C; Cavo M; Garderet L; Ivanova V; Martinez-Lopez J; Belch A; Palumbo A; Schey S; Sonneveld P; Yu X; Sternas L; Jacques C; Zaki M; Dimopoulos M
Lancet Oncol; 2013 Oct; 14(11):1055-1066. PubMed ID: 24007748
[TBL] [Abstract][Full Text] [Related]
6. Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients.
Nooka AK; Joseph NS; Kaufman JL; Heffner LT; Gupta VA; Gleason C; Boise LH; Lonial S
Cancer; 2019 Sep; 125(17):2991-3000. PubMed ID: 31090928
[TBL] [Abstract][Full Text] [Related]
7. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial.
Dimopoulos MA; Terpos E; Boccadoro M; Delimpasi S; Beksac M; Katodritou E; Moreau P; Baldini L; Symeonidis A; Bila J; Oriol A; Mateos MV; Einsele H; Orfanidis I; Ahmadi T; Ukropec J; Kampfenkel T; Schecter JM; Qiu Y; Amin H; Vermeulen J; Carson R; Sonneveld P;
Lancet Oncol; 2021 Jun; 22(6):801-812. PubMed ID: 34087126
[TBL] [Abstract][Full Text] [Related]
8. Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease.
Lacy MQ; Allred JB; Gertz MA; Hayman SR; Short KD; Buadi F; Dispenzieri A; Kumar S; Greipp PR; Lust JA; Russell SJ; Dingli D; Zeldenrust S; Fonseca R; Bergsagel PL; Roy V; Stewart AK; Laumann K; Mandrekar SJ; Reeder C; Rajkumar SV; Mikhael JR
Blood; 2011 Sep; 118(11):2970-5. PubMed ID: 21690557
[TBL] [Abstract][Full Text] [Related]
9. Elotuzumab, pomalidomide, and dexamethasone is a very well tolerated regimen associated with durable remission even in very advanced myeloma: a retrospective study from two academic centers.
Hose D; Schreder M; Hefner J; Bittrich M; Danhof S; Strifler S; Krauth MT; Schoder R; Gisslinger B; Einsele H; Gisslinger H; Knop S
J Cancer Res Clin Oncol; 2021 Jan; 147(1):205-212. PubMed ID: 32683487
[TBL] [Abstract][Full Text] [Related]
10. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.
Attal M; Richardson PG; Rajkumar SV; San-Miguel J; Beksac M; Spicka I; Leleu X; Schjesvold F; Moreau P; Dimopoulos MA; Huang JS; Minarik J; Cavo M; Prince HM; Macé S; Corzo KP; Campana F; Le-Guennec S; Dubin F; Anderson KC;
Lancet; 2019 Dec; 394(10214):2096-2107. PubMed ID: 31735560
[TBL] [Abstract][Full Text] [Related]
11. The European medicines agency review of pomalidomide in combination with low-dose dexamethasone for the treatment of adult patients with multiple myeloma: summary of the scientific assessment of the committee for medicinal products for human use.
Hanaizi Z; Flores B; Hemmings R; Camarero J; Sancho-Lopez A; Salmonson T; Gisselbrecht C; Laane E; Pignatti F
Oncologist; 2015 Mar; 20(3):329-34. PubMed ID: 25673103
[TBL] [Abstract][Full Text] [Related]
12. Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial.
Mateos MV; Blacklock H; Schjesvold F; Oriol A; Simpson D; George A; Goldschmidt H; Larocca A; Chanan-Khan A; Sherbenou D; Avivi I; Benyamini N; Iida S; Matsumoto M; Suzuki K; Ribrag V; Usmani SZ; Jagannath S; Ocio EM; Rodriguez-Otero P; San Miguel J; Kher U; Farooqui M; Liao J; Marinello P; Lonial S;
Lancet Haematol; 2019 Sep; 6(9):e459-e469. PubMed ID: 31327687
[TBL] [Abstract][Full Text] [Related]
13. Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02.
Leleu X; Attal M; Arnulf B; Moreau P; Traulle C; Marit G; Mathiot C; Petillon MO; Macro M; Roussel M; Pegourie B; Kolb B; Stoppa AM; Hennache B; Bréchignac S; Meuleman N; Thielemans B; Garderet L; Royer B; Hulin C; Benboubker L; Decaux O; Escoffre-Barbe M; Michallet M; Caillot D; Fermand JP; Avet-Loiseau H; Facon T;
Blood; 2013 Mar; 121(11):1968-75. PubMed ID: 23319574
[TBL] [Abstract][Full Text] [Related]
14. Pomalidomide alone or in combination with dexamethasone in Japanese patients with refractory or relapsed and refractory multiple myeloma.
Matsue K; Iwasaki H; Chou T; Tobinai K; Sunami K; Ogawa Y; Kurihara M; Midorikawa S; Zaki M; Doerr T; Iida S
Cancer Sci; 2015 Nov; 106(11):1561-7. PubMed ID: 26292221
[TBL] [Abstract][Full Text] [Related]
15. Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma.
Dimopoulos MA; Dytfeld D; Grosicki S; Moreau P; Takezako N; Hori M; Leleu X; LeBlanc R; Suzuki K; Raab MS; Richardson PG; Popa McKiver M; Jou YM; Shelat SG; Robbins M; Rafferty B; San-Miguel J
N Engl J Med; 2018 Nov; 379(19):1811-1822. PubMed ID: 30403938
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed or refractory multiple myeloma.
Cohen A; Spektor TM; Stampleman L; Bessudo A; Rosen PJ; Klein LM; Woliver T; Flam M; Eshaghian S; Nassir Y; Maluso T; Swift RA; Vescio R; Berenson JR
Br J Haematol; 2018 Jan; 180(1):60-70. PubMed ID: 29164606
[TBL] [Abstract][Full Text] [Related]
17. A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma.
Mikhael J; Richardson P; Usmani SZ; Raje N; Bensinger W; Karanes C; Campana F; Kanagavel D; Dubin F; Liu Q; Semiond D; Anderson K
Blood; 2019 Jul; 134(2):123-133. PubMed ID: 30862646
[TBL] [Abstract][Full Text] [Related]
18. [Pomalidomide in the treatment of relapsed and refractory multiple myeloma].
Roziaková L; Mistrík M; Bátorová A
Klin Onkol; 2014; 27(5):318-25. PubMed ID: 25312708
[TBL] [Abstract][Full Text] [Related]
19. Pomalidomide plus low-dose dexamethasone in relapsed refractory multiple myeloma after lenalidomide treatment failure.
Siegel DS; Schiller GJ; Song KW; Agajanian R; Stockerl-Goldstein K; Kaya H; Sebag M; Samaras C; Malek E; Talamo G; Seet CS; Mouro J; Pierceall WE; Zafar F; Chung W; Srinivasan S; Agarwal A; Bahlis NJ
Br J Haematol; 2020 Feb; 188(4):501-510. PubMed ID: 31588567
[TBL] [Abstract][Full Text] [Related]
20. Pomalidomide with or without dexamethasone for relapsed/refractory multiple myeloma in Japan: a retrospective analysis by the Kansai Myeloma Forum.
Matsumura-Kimoto Y; Kuroda J; Kaneko H; Kamitsuji Y; Fuchida SI; Nakaya A; Shibayama H; Uoshima N; Yokota I; Uchiyama H; Yagi H; Kosugi S; Matsui T; Ishikawa J; Matsuda M; Ohta K; Iida M; Tanaka H; Kobayashi M; Wada K; Shimazaki C; Nomura S; Imada K; Hino M; Matsumura I; Kanakura Y; Takaori-Kondo A;
Int J Hematol; 2018 May; 107(5):541-550. PubMed ID: 29380179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
